The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced that Dr. Jonathan Arambula will join The iQ Group Global as the Vice President of Research, OncoTEX Inc. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its novel anticancer drug platform, TEX […]

One of the world’s most renowned Chemists and co-founder of the biopharmaceutical company, Pharmacyclics, Professor Jonathan L. Sessler has been appointed as a Non-Executive Director to the board of OncoTEX Inc., it was announced today. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its […]

SYDNEY –  The iQ Group Global has announced its equity crowd-sourced funding platform Capital Labs has launched a new investment offer, driving a new era in Australian Healthcare. One of the first ASIC authorised equity crowd-sourced funding (CSF) platforms in Australia, Capital Labs only partners with companies launching technology and innovations that have a positive […]

FarmaForce has set a new standard for sales excellence after being recognised as Sales Team of the Year for the fourth consecutive year at the 15th annual PRIME Awards. The FarmaForce Nephrology Specialist Team, an Otsuka Australia and FarmaForce strategic partnership, won the 2019 Sales Team of the Year award for exceptional sales, excellence in […]

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today announced it has added a novel anticancer drug platform to its portfolio that has the ability to develop a range of cancer therapeutics. TEX Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable […]

Morningstar have recently released quantitative research reports on two iQGG ASX-listed companies: iQ3 Corp (ASX:IQ3) FarmaForce (ASX:FFC)

The iQ Group Global is honoured to be recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine in its relentless pursuit to create the medicines of tomorrow. The iQ Group Global ranked #5 on the Health Industries list, from more than 800 nominated […]

The iQ Group Global continued its commitment to unearthing cutting edge research in biosciences by supporting the Diabetes Australia Research awards last month. The awards, presented at NSW Parliament House on July 19, honour the people and institutions behind the research contributing to the prevention, management and cure for all types of diabetes.  Diabetes Australia […]

The iQ Group Global has been recognised by Med Tech Outlook magazine as one of the Top 10 Diabetes Care Solutions Providers in 2019. The Saliva Glucose Biosensor is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva, not blood. With this world-first technology, our global mission is to […]

Last night’s 2018 Federal budget saw a raft of funding and exciting initiatives aimed at further supporting Australia’s position as a global medical technology leader. Here’s how: Supporting Medical Research A 21st Century Medical Industry Growth Plan will deliver $1.3 billion to support Australia as a global health industry leader in medical technology, biotechnology and pharmaceuticals […]